Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients

Trial Profile

Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs Gemcitabine (Primary) ; Romidepsin (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms FIL-GEMRO
  • Most Recent Events

    • 30 Aug 2018 Status changed from active, no longer recruiting to completed.
    • 07 Feb 2018 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 28 Jan 2016 Planned End Date changed from 1 Sep 2015 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top